Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Neuroendocrine × Somatostatin × 1 year × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 6 Ipilimumab 5 Cisplatin 5 atezolizumab 4 Carboplatin 4 Etoposide 3 gallium Ga 68 dotatate 2 dostarlimab 2 Temozolomide 2 Positron Emission Tomography Computed Tomography 2 Paclitaxel 2 Magnetic Resonance Imaging 2 Immunoglobulin G 2 Drug Therapy 2 Disulfides 2 zimberelimab 1 tivozanib 1 repotrectinib 1 pralsetinib 1 pembrolizumab 1 niraparib 1 lutetium Lu 177 dotatate 1 iadademstat 1 durvalumab 1 cabozantinib 1 budigalimab 1 berzosertib 1 belinostat 1 Topotecan 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04464122 2025-04-03

REBORN

University of Roma La Sapienza

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡